Danmark - dansk - SEGES Landbrug & Fødevarer

adama northern europe b.v. - trinexapac-ethyl, trinexapac - flydende middel - 175 g/l trinexapac-ethyl ; (~ 156 g/l trinexapac

Danmark - dansk - SEGES Landbrug & Fødevarer

adama northern europe b.v. - trinexapac-ethyl, trinexapac - emulsionskoncentrat - 175 g/l trinexapac-ethyl ; (~ 156 g/l trinexapac

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - moxifloxacinhydrochlorid - infusionsvæske, opløsning - 1,6 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

rivopharm limited - moxifloxacinhydrochlorid - filmovertrukne tabletter - 400 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm generics a/s - natriumpicosulfat - orale dråber, opløsning - 7,5 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

noridem enterprises ltd. - bupivacainhydrochlorid monohydrat - injektionsvæske, opløsning - 2,5 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - andre narkotika stoffer - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Danmark - dansk - Adama

adama - cs - clomazon 360 g/ - herbicider

Den Europæiske Union - dansk - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - andre narkotika stoffer - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.